Trial Profile
A Phase 1, Double-blind, Placebo-controlled, Single Ascending Dose Study of the Safety, Tolerability and Pharmacokinetics of CPP-115 Solution Administered Orally to Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 22 Apr 2021
Price :
$35
*
At a glance
- Drugs CPP 115 (Primary)
- Indications Cocaine-related disorders; Infantile spasms; Partial epilepsies
- Focus Adverse reactions
- Sponsors Catalyst Pharmaceuticals
- 22 May 2012 Status changed from active, no longer recruiting to completed.
- 17 May 2012 Planned End Date changed to 1 Jul 2012, as reported by ClinicalTrials.gov
- 17 May 2012 New source identified and integrated (ClinicalTrials.gov)